Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer

Ikagawa,Makiko; Kimura,Michio; Iwai,Mina; Usami,Eiseki; Yoshimura,Tomoaki; Yasuda,Kimio

doi:10.3892/mco.2016.940

Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer

Authors:
- Makiko Ikagawa
- Michio Kimura
- Mina Iwai
- Eiseki Usami
- Tomoaki Yoshimura
- Kimio Yasuda
View Affiliations

Affiliations: Faculty of Pharmaceutical Sciences, Kinjo Gakuin University, Nagoya, Aichi 463‑8521, Japan, Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu 503‑8502, Japan
Published online on: June 24, 2016 https://doi.org/10.3892/mco.2016.940
Pages: 283-288

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this retrospective study was to investigate the safety of S‑1 as second‑line therapy and to evaluate the association between neutropenia occurring during first‑line gemcitabine (GEM) therapy and survival for advanced or recurrent pancreatic cancer (APC). Between January, 2010 and December, 2014, 123 APC patients received chemotherapy at the Ogaki Municipal Hospital (Ogaki, Japan). Of those, 37 received GEM as first‑line and S‑1 as a second‑line therapy (GEM→S‑1 group). A further 60 patients received GEM as first‑line therapy, but did not receive second‑line therapy (GEM group). The median overall survival in the GEM→S‑1 (n=37) and GEM (n=60) groups was 323 days [95% confidence interval (CI): 138‑218.9 days] and 172 days (95% CI: 105‑184.4 days), respectively (P=0.0004). The median overall survival in the mild (grade ≤2; n=63) and severe (grade ≥3; n=34) neutropenia groups was 178 days (95% CI: 182‑275 days) and 330 days (95% CI: 297‑514 days), respectively (log‑rank test, P=0.0023). The severe non‑haematological toxicities associated with S‑1 as second‑line therapy were nausea (2.7%) and hand‑foot syndrome (2.7%). Second‑line S‑1 treatment was discontinued due to adverse events in 5.4% (2̸37) of the cases. In conclusion, neutropenia occurring during GEM therapy administered as first‑line treatment to APC patients was strongly associated with a better prognosis. S‑1 therapy as second‑line treatment was associated with a low incidence of severe adverse events and the patients were able to successfully continue treatment.

View Figures

View References

1	Matsuda T, Ajiki W, Marugame T, Ioka A, Tsukuma H and Sobue T: Research Group of Population-Based Cancer Registries of Japan: Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: A chronological and international comparative study. Jpn J Clin Oncol. 41:40–51. 2011. View Article : Google Scholar : PubMed/NCBI
2	Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997.PubMed/NCBI
3	Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, Fukutomi A, Sugimori K, Baba H, Yamao K, et al: Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI
4	Hatori M, Tsuji D, Taku K, Daimon T, Kamezato M, Ikeda M, Makuta R, Hayashi H, Inoue K and Itoh K: Prognostic factors in patients with unresectable pancreatic cancer treated with gemcitabine: a retrospective analysis. Jpn J Pharm Health Care Sci. 40:734–741. 2014. View Article : Google Scholar
5	Teramukai S, Kitano T, Kishida Y, Kawahara M, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, et al: Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: An analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer. 45:1950–1958. 2009. View Article : Google Scholar : PubMed/NCBI
6	An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH and Jiang WQ: Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 15:516–522. 2010. View Article : Google Scholar : PubMed/NCBI
7	Stotz M, Gerger A, Eisner F, Szkandera J, Loibner H, Ress AL, Kornprat P, AlZoughbi W, Seggewiesn FS, Lackner C, et al: Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer. Br J Cancer. 109:416–421. 2013. View Article : Google Scholar : PubMed/NCBI
8	Shitara K, Matsuo K, Takahari D, Yokota T, Shibata T, Ura T, Ito S, Sawaki A, Tajika M, Kawai H and Muro K: Nuetropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol. 21:2403–2409. 2010. View Article : Google Scholar : PubMed/NCBI
9	Shitara K, Matsuo K, Oze I, Mizota A, Kondo C, Nomura M, Yokota T, Takahari D, Ura T and Muro K: Meta-analysis of neutropenia or leukopenia as a prognostic factor in patients with malignant disease undergoing chemotherapy. Cancer Chemother Pharmacol. 68:301–307. 2011. View Article : Google Scholar : PubMed/NCBI
10	Shitara K, Matsuo K, Takahari D, Yokota T, Inaba Y, Yamaura H, Sato Y, Najima M, Ura T and Muro K: Neutropaenia as prognostic factor in metastatic colorectal cancer patients undergoing chemotherapy with first-line FOLFOX. Eur J Cancer. 45:1757–1763. 2009. View Article : Google Scholar : PubMed/NCBI
11	Kawashima H, Itoh A, Ohno E, Nakamura M, Miyahara R, Ohmiya N, Hara K, Kanamori A, Itoh T, Taki T, et al: Prospective multicenter study to investigate the introduction rate of second-line S-1 in gemcitabine-refractory unresectable pancreatic cancer. Cancer Chemother Pharmacol. 68:677–683. 2011. View Article : Google Scholar : PubMed/NCBI
12	Nakai Y1, Isayama H, Sasaki T, Sasahira N, Kogure H, Hirano K, Tsujino T, Ijichi H, Tateishi K, Tada M, et al: Impact of S-1 in patients with gemcitabine-refractory pancreatic cancer in Japan. Jpn J Clin Oncol. 40:774–780. 2010. View Article : Google Scholar : PubMed/NCBI
13	Nakai Y1, Isayama H, Sasaki T, Sasahira N, Ito Y, Kogure H, Togawa O, Matsubara S, Arizumi T, Yagioka H, et al: Impact of S-1 on the survival of patients with advanced pancreatic cancer. Pancreas. 39:989–993. 2010. View Article : Google Scholar : PubMed/NCBI
14	Takasawa O, Fujita N, Noda Y, Kobayashi G, Ito K, Obana T, Horaguchi J, Koshita S, Kanno Y, Suzuki T, et al: Second-line treatment with S-1 in advanced pancreatic cancer. Gastroenterology. 48:207–213. 2009.
15	Kimura M, Morihata K, Ito D, Iwai M, Okada K, Usami E, Nakao T, Yoshimura T and Yasuda T: Continuous administration and safety of S-1 in adjuvant chemotherapy for gastric cancer. Cancer & chemotherapy. 37:829–834. 2010.(In Japanese).
16	Kimura M, Usami E, Yoshimura T, Yasuda T, Kaneoka Y, Teramachi H, Sugiyama T and Tsuchiya T: Pharmaceutical care for patients undergoing S-1 plus cisplatin therapy for unresectable recurrent gastric cancer. J Pharm Pract. 26:409–414. 2013. View Article : Google Scholar : PubMed/NCBI
17	Fridlender ZG and Albelda SM: Tumor-associated neutrophils: Friend or foe? Carcinogenesis. 33:949–955. 2012. View Article : Google Scholar : PubMed/NCBI
18	Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, Yamazaki K, Taku K, Machida N, Sakamoto T and Tomita H: S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol. 40:567–572. 2010. View Article : Google Scholar : PubMed/NCBI